About

Kris Vaddi, Ph.D. founded Prelude Therapeutics and has served as the Chief Executive Officer and member of the Board of Directors since 2016. Prior to founding Prelude, from 2014 to 2016, Dr. Vaddi served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Previously, he held several roles at Incyte Corporation, starting as a Founding Scientist and an Executive Director in 2002, and most recently as a Senior Advisor from 2015 to 2016. Dr. Vaddi initiated and championed JAK research programs at Incyte that led to the discovery, development, and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (baricitinib) for rheumatoid arthritis. He received his BVSc in Veterinary Medicine from APAU in India and his Ph.D. in Pharmacology and Toxicology from University of Florida.

Peggy Scherle, Ph.D. has served as Chief Scientific Officer at Prelude Therapeutics since 2018. Prior to joining Prelude, Dr. Scherle held several roles at Incyte Corporation, most recently serving as Group Vice President, Discovery Biology and Preclinical Pharmacology where she oversaw the target validation and preclinical drug discovery efforts. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Dr. Scherle was one of the original team of scientists that joined Incyte in 2002 and was involved in the discovery and development of the JAK inhibitors, Jakafi® (ruxolitinib), for the treatment of myelofibrosis and polycythemia vera, and Olumiant® (baricitinib), for rheumatoid arthritis, as well as the advancement of >10 small molecules into clinical studies for cancer, including both targeted therapy and immunotherapy approaches. Prior to Incyte, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals Company and Bristol- Myers Squibb. Dr. Scherle received her Ph.D. in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH.

Andrew Combs, Ph.D. is the Executive Vice President and Head of Chemistry at Prelude Therapeutics. Dr. Combs joined Prelude in 2019 and has over 23 years of experience as a medicinal chemist. Prior to joining Prelude, Dr. Combs previously held several roles at Incyte Corporation, most recently as Vice President of Discovery Chemistry, where he led teams in medicinal chemistry, analytical chemistry, enabling technologies, computational design, and informatics from 2003 until 2019. Earlier in his career, Dr. Combs held positions of increasing responsibility, starting as a Senior Research Scientist and advancing to a Director of medicinal chemistry at DuPont-Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb. His passion for research embraces the application of innovative and enabling technologies to expedite the drug discovery process. He has led teams of creative chemists with whom he co-invented >10 clinical candidates, including epacadostat and parsaclisib, which both entered late stage clinical trials in oncology. Dr. Combs holds B.S. degrees in Chemistry and Molecular Biology from the UW-Madison, a Ph.D. in Organic Chemistry from UCLA, and completed his training as a HHMI post-doctoral fellow at Harvard University.

Deborah Morosini, M.D., M.S.W. joined Prelude Therapeutics in 2020 and currently serves as Executive Vice President and Chief of Clinical Affairs. She brings to Prelude extensive expertise in oncology drug development, clinical genomics, and philanthropic activism. She previously served as Vice President of Clinical Affairs and Patient Engagement (Chief Patient Officer) at Loxo Oncology, where she built and led patient engagement and enrollment strategy, medical affairs, and patient advocacy. Dr. Morosini played a key role in the launch of Vitrakvi® (larotrectinib) via a co-promote partnership with Bayer, and conducted launch preparations for LOXO-292, a RET inhibitor for lung and thyroid cancer. Prior to Loxo, she was an early team member at Foundation Medicine, where she developed a niche specialty in the genomics of adolescent and young adult cancer. Before joining Foundation Medicine, she founded and led the molecular pathology group at AstraZeneca Pharmaceuticals, where she helped develop and implement biomarker strategies for biomarker-driven trials. Prior to AstraZeneca, Dr. Morosini served as Director of Pathology for Ardais, a clinical genomics biotechnology company. She has been featured as a spokesperson for numerous non-profit and government events in oncology and has provided expert commentary for national broadcast media. She has served on numerous national oncology non-profit boards, and currently serves on the Board of Directors for ClinWiki and the SAB for Target Cancer and Upstage Lung Cancer. Dr. Morosini earned her B.A. in English from Mount Holyoke College, her M.S.W. from NYU Graduate School of Social Work, and her M.D. from Boston University School of Medicine. She completed a pathology residency at Boston Medical Center.

Aimee Crombie, Ph.D. is Senior Vice President and Head of Strategic Planning & Operations at Prelude Therapeutics. Prior to joining Prelude, she was Vice President of Research at Trevena, Inc. where she oversaw drug discovery activities supporting target and hit identification, chemical lead optimization, and drug candidate selection. Aimee has contributed to the discovery of several small molecule including oliceridine, TRV734, and TRV250, biased agonists of GPCRs that are being developed for the treatment of CNS disorders. Prior to joining Trevena, Aimee was a member of the Discovery Medicinal Chemistry group at Pfizer (formerly Wyeth) where she contributed to research programs in a variety of therapeutic areas including oncology, inflammation, neuroscience, cardiovascular, and musculoskeletal diseases. Aimee received her B.S. in Chemistry from the University of Pittsburgh and her Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.

Adam Shilling, Ph.D. is Vice President Early Development and Regulatory Affairs at Prelude Therapeutics with 20 years of pharmaceutical experience spanning all phases of clinical and preclinical development. Prior to joining Prelude, Adam was Executive Director of Global Regulatory Affairs at Incyte where he was the global regulatory lead for the GVHD franchise and JAK1 programs. Adam led the NDA submission and approval of Jakafi in acute GVHD and contributed to the development and NDA approvals for Jakafi in myelofibrosis and polycythemia vera and Olumiant in rheumatoid arthritis. Prior to Incyte, Adam was Principal Research Scientist at Wyeth, contributing to programs in infectious diseases, women’s health, and neuroscience, including the NDA for Pristiq in major depressive disorders. He received his BS in Marine Biology at LIU Southampton and PhD in Toxicology at Oregon State University.

Madhu Pudipeddi, Ph.D. is Senior Vice President of Technical Operations at Prelude Therapeutics. Prior to joining Prelude, he was Executive Director at Novartis Pharmaceuticals, where he had roles of increasing responsibility for over 16 years in the areas of drug development and technical operations. Dr. Pudipeddi contributed to the development and commercialization of several new molecular entities, build-up of an R&D organization in India, and oversaw Manufacturing Science & Technology operations in Europe and Americas. Prior to joining Novartis, Dr. Pudipeddi was at Bristol-Myers Squibb where he was engaged in drug discovery-development collaboration and development of new molecular entities. Dr. Pudipeddi received his B.S. in Pharmaceutical Sciences from Andhra University, India and his Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison.

Michele Porreca, M.B.A., joined Prelude Therapeutics in June 2021 to serve in the newly created position of Chief People Officer where she will lead all aspects of the Company’s human resources management, including, talent management and strategy, organizational effectiveness, total rewards, culture, inclusion, and employee communications. Ms. Porreca brings more than 20 years of experience in human resources with over a decade of specialized experience in the pharmaceutical and biopharmaceutical sector. Most recently, she served as CHRO at Nabriva Therapeutics, where she led the human resources function during its transition from a clinical stage to commercial stage infectious disease organization. Prior to Nabriva, she served as the Vice President, Human Resources at Synergy Pharmaceuticals during the launch of its first specialty product. In addition, Ms. Porreca was a member of the HR leadership team at Shire Pharmaceuticals during a six-year span of rapid growth and partnered with global leaders across rare disease and specialty pharma lines of business as well corporate functions. In addition to her time in life sciences, Ms. Porreca held HR leadership roles in both the medical and tech industries. Ms. Porreca earned a B.A from Ursinus College and an M.B.A from Drexel University.

Laurent Chardonnet is Chief Financial Officer of Prelude Therapeutics. Prior to Prelude, he served as Senior Vice President, Chief Financial Officer at Axcella Health. Prior to Axcella, he spent 15 years at Incyte Corporation where he held roles of increasing responsibility including Vice President Finance, Treasurer and Principal Accounting Officer, Head of Finance and Administration for the company’s European division, and Vice President of Alliances and Global Strategy. Mr. Chardonnet received his Master of Business Administration from Vanderbilt University and his initial business degree from the Institut Supérieur de Gestion in Paris.

Naveen Babbar is Senior Vice President, Translation Medicine. Before joining Prelude, Naveen was Vice President of Global Precision Medicine at Novartis Pharmaceuticals. Naveen’s experience covers a wide span of solid tumor oncology drug and device development including translational studies across early and late-stage development, diagnostic assay development, global registrations and commercial launches. Naveen has contributed to successful NDA submissions for Zykadia® (ALK inhibitor), Kisqali® (CDK4/6 inhibitor), Piqray® (PIK3CA inhibitor) and Tabrecta® (cMET inhibitor), and their associated companion diagnostic assays globally. Naveen received his M.Sc. in Biotechnology from Delhi, India, Ph.D. in Biochemistry and Molecular Biology from University of Arizona and completed his postdoctoral fellowship from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.